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ABSTRACT 
Background: Protracted bacterial bronchitis (PBB) and bronchiectasis are distinct diagnostic 
entities that share common clinical and laboratory features. It is postulated, but remains unproven, 
that PBB precedes a diagnosis of bronchiectasis in a subgroup of children. In a cohort of children 
with PBB, our objectives were to: (a) determine the medium-term risk of bronchiectasis and (b) 
identify risk factors for bronchiectasis and recurrent episodes of PBB. 
Methods: 161 children with PBB and 25 controls were prospectively recruited to this cohort 
study. A subset of 106 children was followed for 2 years. Flexible bronchoscopy, BAL and basic 
immune function tests were performed. CT chest was undertaken if clinical features were 
suggestive of bronchiectasis. 
Results: Of 161 children with PBB (66% male), 13 (8.1%) were diagnosed with bronchiectasis 
over the study period. Almost half (43.5%) with PBB had recurrent episodes (>3/year). Major 
risk factors for bronchiectasis included: H. influenzae lower airway infection (in BAL) (p=0.013) 
and recurrent episodes of PBB (p=0.003). H. influenzae infection conferred >7 times higher risk 
of bronchiectasis [HR 7.55 (95%CI 1.66 - 34.28), p=0.009] compared to absence of H. influenzae. 
The majority of isolates (82%) were nontypeable H. influenzae. No risk factors for recurrent PBB 
were identified.  
Conclusions: PBB is associated with a future diagnosis of bronchiectasis in a subgroup of 
children. H. influenzae lower airway infection and recurrent PBB are significant predictors. 
Clinicians should be cognisant of the relationship between PBB and bronchiectasis and 
appropriate follow-up measures should be taken in those with risk factors. 
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INTRODUCTION 
Protracted bacterial bronchitis (PBB), first described in 2006, is a major cause of chronic cough 
in children.1,2 PBB has been studied by research groups in Australia,1-3 Europe 4 and the US with 
similar findings.5,6 PBB is characterised by persistent wet cough, response to 2-weeks of 
appropriate antibiotic therapy and absence of indicators to suggest an alternative cause for 
cough.1,7 PBB is more common in young boys and children who have attended childcare.8 When 
compared to controls, children with PBB are more likely to have lower airway infection with 
common respiratory bacteria and viruses.8  
 
Currently, there are limited published data,9 and no prospective follow-up studies, evaluating the 
outcomes of children with PBB. This research gap limits the clinician’s ability to prognosticate 
on the likely natural history of PBB in any given child. Anecdotally, many otherwise healthy 
children experience recurrent episodes of PBB without appreciable longer-term consequences. 
However, in a subgroup of children, recurrent PBB appears to be associated with a future 
diagnosis of bronchiectasis.   
  
PBB and bronchiectasis share many common features, spanning from respiratory symptoms (i.e. 
chronic wet cough) to intense neutrophilic lower airway inflammation and innate immune system 
activation.10-12 Lower airway microbiota,13 including presence of adenovirus type C 14 and 
predominance of non-typeable Haemophilus influenzae (NTHi)1,8 are also alike. These 
similarities underpin the notion that PBB and bronchiectasis represent a clinical continuum.15,16 
To date, the accuracy of this proposed continuum is uncertain and warrants evaluation in a 
prospective cohort study.  
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Hence, in 161 children with PBB and 25 controls, we aimed to determine: (a) the 2-year 
outcomes of children with PBB with respect to a diagnosis of bronchiectasis and; (b) risk factors 
for bronchiectasis and for recurrent episodes of PBB.  
 
MATERIALS AND METHODS 
Study participants 
Participants were enrolled as part of a larger prospective cohort study aimed at evaluating the 
long-term outcome of children with chronic cough. Written informed consent was obtained from 
all parents/guardians and ethics approval granted by The Queensland Children’s Health Services 
(RCH) Human Research Ethics Committee (HREC/03/QRCH/17).  
 
Between March 2008 and October 2012, 343 children were enrolled. Of these, 161 fulfilled 
criteria for PBB and 25 were recruited as control participants (15 undergoing evaluation for 
respiratory symptoms other than chronic cough, and 10 healthy controls). Data from the 15 
children undergoing respiratory evaluation have previously been described8 (e-supplement 1). 
The 10 healthy controls were recruited from colleagues and friends.  
 
All children (excluding the 10 healthy controls) underwent flexible bronchoscopy and broncho-
alveolar lavage (BAL) as per clinical indication, and were recruited prior to their bronchoscopy. 
BALs were processed for cellularity and microbiology. Bacterial infection was defined as 
bacterial load of ≥104 colony-forming units (cfu)/ml BAL.8,11 Laboratory tests for suppurative 
lung diseases were performed, as described previously.14 Haemophilus influenzae 
characterisation was undertaken at a research laboratory (Menzies School of Child Health 
Research, Darwin) when BAL was available (e-supplement 2).  
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Follow-up 
Follow-up included monthly contact (phone-calls or emails by research nurses) to capture 
respiratory exacerbations. Parents completed cough diaries during periods of illness. Antibiotic 
therapy was usually prescribed by their family doctor when appropriate, as per usual clinical 
management. The majority of children were seen by their pediatric pulmonologist 3-4 monthly as 
part of routine clinical follow-up.  At 2-years a subset (n=106) also underwent clinical 
assessment for bronchiectasis (DW and/or AC). 
  
Given the ethical considerations pertaining to research-related CT chest in children,17,18 CT scans 
were only performed when clinical features of bronchiectasis were present.19 Clinicians had 
similar practices whereby CT chest was undertaken for: (a) chronic wet cough non-responsive to 
4 weeks of antibiotic therapy;20 (b) persistent chest radiographic changes despite appropriate 
antibiotic therapy or (c) recurrent hospitalisations for acute respiratory events.  
 
Definitions 
PBB was defined as: (i) history of chronic (≥ 4 weeks) wet cough, (ii) prospective evidence 
(supported by cough diaries) of response to 2 weeks of treatment with amoxicillin-clavulanate 
and (iii) absence of clinical pointers suggesting an alternative cause for cough.1 Bronchiectasis 
diagnosis was based on pediatric radiological (CT) criteria,21 in the context of a child having 
clinical symptoms of bronchiectasis. Two respiratory physicians, blinded to each other’s 
assessment, reviewed all CT images. Recurrent PBB was defined as >3 episodes of PBB in the 
first year after enrolment. 
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Statistical analyses 
Descriptive statistics were utilized to summarize demographic and clinical characteristics. 
Median and inter-quartile ranges were reported as data were non-normally distributed. Pearson’s 
chi-square (or Fisher’s exact test) was used for categorical and Mann-Whitney U for continuous 
variables. Logistic regression was employed to calculate odds ratios (OR) and 95% confidence 
intervals (95%CI). A survival analysis (using Cox’s proportional hazards regression) examined 
the relationship between time to diagnosis of, and risk factors for, bronchiectasis. A 2-tailed p-
value of <0.05 was considered statistically significant. Statistical analyses were performed using 
SPSS (version 21.0, Armonk, NY: IBM Corp.,USA) and STATA (version 12.1, StataCorp, 
Texas,USA). 
 
RESULTS 
Clinical and demographic characteristics of participants  
Of the 161 children with PBB, 106 completed the 2-year follow-up period and had clinician 
assessment for bronchiectasis (Figure 1). The median duration of follow-up was 25 months (IQR 
24, 28) in children with PBB and 27 months (IQR 26, 29) in controls undergoing bronchoscopy. 
  
There was no difference between children who completed the 2-year follow-up and those who 
did not (Table 1), with regards to: length of cough at recruitment (p=0.807), H. influenzae status 
(p=0.518) or proportion with 2+ siblings (p=0.260). However, those completing the 2-year 
follow-up (n=106) were significantly more likely to have had recurrent PBB (p=0.003). Thus, to 
reduce the potential for bias, 161 was used as the denominator in subsequent analyses. The 55 
additional children who did not complete 2-year follow-up were assumed to be bronchiectasis-
free at the 2-year time-point. We assumed this as, when these families were contacted by phone, 
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the vast majority of children had had resolution of their chronic cough. Comparison of groups at 
baseline showed that children with PBB had a higher burden of doctor visits in the preceding 12 
months, as compared to controls (Table 1).  
 
At 2-year follow-up, compared to controls, children with PBB were more likely to be coughing 
(44% vs 12%, p=0.005) and to be receiving antibiotic therapy (20% vs 0, p=0.012). The burden 
of doctor visits (in previous 5 years) was higher in the children with PBB compared to controls 
(44% vs 5%, p=0.001) and those with PBB were more likely to have had parent-reported wheeze 
in the preceding 12 months (58% vs 16%, p=0.001). Of the 161 children with PBB, 154 had 
completed cough diaries until at least the 1-year time-point. Of these, 67 (43.5%) had recurrent 
PBB (>3 episodes/year). 
 
 
Bronchiectasis diagnoses on chest CT scan 
Multi-detector CT with HRCT reconstruction was performed in 25 of 161 children with PBB. 
Radiological evidence of bronchiectasis was present in 13 (8.1%) and all had mild (i.e. 
cylindrical bronchiectasis). CT was performed at median duration of 9 months (IQR 4, 19) post 
recruitment. Their median age was 38 months (IQR 27, 58).  
 
Compared to those that did not undergo CT, children with PBB who underwent CT chest, had 
similar rates of lower airway infection with H. influenzae (p=0.142) and S. pneumoniae 
(p=0.135), however, those undergoing CT scan were less likely to have M. catarrhalis infection, 
than those that did not undergo CT (34.2% vs 17%, p=0.029) (likely to have been a chance 
occurrence.) Similar rates of ‘recurrent PBB’ status were recorded in those undergoing CT and 
those that did not (p=0.118).  
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No children in the control group developed clinical features of bronchiectasis. Of the control 
children, 3 had CT scan performed for other indications. None had bronchiectasis. 
 
Risk factors for bronchiectasis and recurrent PBB 
Univariate analysis showed that bronchiectasis was significantly more likely to be diagnosed 
during follow-up when the child had recurrent PBB, when H. influenzae infection was present 
(i.e. cultured at a clinically significant level of ≥104 cfu/ml in BAL) or in children with two or 
more siblings (Table 2). There were no significant inter-group differences for other factors.  
 
Multivariate logistic regression showed that recurrent PBB status and H. influenzae infection 
were significantly associated with bronchiectasis diagnosis [OR 11.48 (95%CI 2.33-56.50) 
p=0.003 and OR 7.60 (95%CI 1.53-37.79), p=0.013, respectively], whereas having ≥2 siblings 
was no longer significant [OR 3.53 (0.98, 12.70), p=0.054]. Survival analysis, using Cox 
regression, concurred with logistic regression findings. Participants with H. influenzae lower 
airway infection were > 7 times more likely to be diagnosed with bronchiectasis per month of 
follow-up, compared to those without H. influenzae, and recurrent PBB status conferred > 9 
times greater risk of bronchiectasis diagnosis per month (Table 3).  
 
The percentage of lower airway neutrophils was similar in children with and without a 
subsequent diagnosis of bronchiectasis [BAL neutr% 35 (12, 75) vs 25 (10,55), p=0.35] in the BE 
present and absent groups respectively. Total cell counts, percentage macrophages and 
percentage lymphocytes were similar between groups. Although the percentage of eosinophils in 
BAL was slightly higher in those who developed bronchiectasis [BAL eosin% 1 (0, 2) vs 0 (0,0), 
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p=0.001], the median eosinophil count was within the normal range (i.e. <2.5%),22 and hence this 
finding was considered to be clinically insignificant. Further, the difference was no longer 
observed when the major outlier was removed.  
 
In the examination of predictors for recurrent PBB, univariate and multivariate analysis showed 
no significant difference between children with and without recurrent PBB for the factors 
examined (sex, age, prior pneumonia, tobacco smoke exposure, maternal tobacco smoking in 
pregnancy, Indigenous status, number of children in household, childcare attendance and BAL 
cellularity and microbiology) (e-Table 1). Notably, H. influenzae infection in BAL did not predict 
recurrent PBB.  
 
H. influenzae typing 
Thirty-four of 55 (62%) H. influenzae positive samples were available for further characterization. 
Of these, H. influenzae from the majority of samples (n=28; 82%) were identified as NTHi; 
encapsulated H. influenzae were not identified. H. influenzae from the remaining 6 samples 
were reassigned as H. haemolyticus following species-specific PCR.  
 
DISCUSSION 
This is the first prospective longitudinal cohort study of children with PBB. In our cohort, based 
in a large tertiary paediatric hospital, almost 44% had recurrent episodes (>3 episodes in the first 
year after recruitment) and approximately 1 in 12 were diagnosed with bronchiectasis at 2-years. 
We identified 2 significant risk factors for bronchiectasis: recurrent (>3 /year) episodes of PBB 
and presence of H. influenzae infection of the lower airways. Further, H. influenzae infection, 
compared to no infection, conferred >7 times higher risk of bronchiectasis diagnosis.  
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Findings from this study, the first to investigate the 2-year outcomes of children with PBB, 
support the hypothesis that PBB and bronchiectasis represent a clinical spectrum. Children with 
PBB have endobronchial bacterial infection and neutrophilic airway inflammation, factors known 
to be injurious to the airways.23 Our findings suggest that, in a subset of children, receiving close 
follow-up by pediatric pulmonologists, recurrent episodes (>3 per year) of PBB precede a 
diagnosis of bronchiectasis. Further, although a cause-effect relationship cannot be concluded, an 
association between H. influenzae infection and bronchiectasis has been shown. This finding is in 
accordance with the increasing recognition of the role of H. influenzae in the pathogenesis of 
chronic respiratory diseases.24 
 
H. influenzae is the most common bacterial species infecting the lower airways of children with 
endobronchial suppuration, including PBB,8 recurrent or non-responsive community-acquired 
pneumonia 25 and bronchiectasis.8,10,26 H. influenzae is also the major bacterial pathogen 
associated with chronic respiratory disorders in adults e.g. bronchiectasis and COPD.24,27,28 
Although H. influenzae infection may be an important risk factor for bronchiectasis,26,29-32 there 
are likely to be other contributory factors.  
 
Our earlier studies identified children with PBB to be significantly more likely than controls, to 
have attended childcare, and to have viral infection of their lower airways, particularly with 
adenovirus type C.8,14 It is plausible, although beyond the scope of this study, that co-infection 
with specific pathogens e.g. adenovirus C and H. influenzae,33 initiates the vicious cycle of lower 
airway infection and inflammation inherent to these conditions.34 Factors such as young age at 
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initial infection (and concomitant immune and respiratory system immaturity), may also play a 
key role in aetio-pathogenesis.14 
 
In this study, bronchiectasis was diagnosed at an early age (median 38 months), similar to our 
other cohorts of children with bronchiectasis.10,20,35 Together with findings from earlier studies on 
PBB,8,14 this observation lends further support to the assertion that timing of airway infection 
(with bacteria and/or viruses), with respect to age, is likely to be important.14 All children had 
mild or early cylindrical bronchiectasis where it is potentially reversible if treated early and 
intensively,36-38 prior to development of severe (saccular or cystic) bronchiectasis.   
 
In support of previous studies on PBB, the present study showed that PBB is characterised by 
active lower airway neutrophilic inflammation. Although the median neutrophil percentage in 
BAL was greater in children with PBB who were subsequently diagnosed with bronchiectasis, 
compared to those who were not (median 35 vs 25, respectively), this difference was not 
significant. This suggested that the degree of airway neutrophilia did not predict bronchiectasis. 
Regarding the inter-group disparity in airway eosinophil levels between those with and without 
bronchiectasis, this is unlikely to be of clinical relevance for two reasons. First, eosinophil levels 
in both groups were within normal reported ranges, and second, when the major outlier was 
removed (16% eosinophils in a child with features consistent with persistent asthma in addition to 
PBB), the difference was no longer significant.  
 
Several limitations to this study merit discussion. The most significant limitation is the fact that  
we did not perform CT scans on all children at study entry and exit. Given the potential increased 
lifetime risk of cancer associated with exposure to CT scans (and the relatively common nature of 
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PBB in otherwise well children)39 we could not justify performing 2 CT scans on every child.18 
The impact of this limitation is two-fold. First, bronchiectasis may have been missed in some 
children at recruitment and indeed at follow-up. Hence, we cannot conclude that PBB progresses 
to bronchiectasis per se. Rather, our findings indicate that, in children with PBB (who are 
followed closely by pulmonologists) a proportion (approximately 8%) will be diagnosed with 
bronchiectasis on CT chest at 2 years. Second, we acknowledge the fact that performing CT scan 
only in a select subgroup introduces the possibility of selection bias in that individual clinicians 
may have different indications for performing CT chest. To address this, we compared children 
with PBB undergoing CT chest to those who did not and found no significant differences 
between groups with respect to bronchiectasis risk factors.  
 
To definitively address our major research question, an ideal study design would include a large 
cohort of healthy (cough-free) children. CT scan, to investigate for bronchiectasis, would need to 
be performed both at study entry and exit. Multiple lower airway samples, collected over time, in 
addition to clinical data on cough and episodes of PBB, would need to be obtained. This would 
elucidate the temporal sequence of lower airway infection, symptom onset and bronchiectasis. 
Additionally, study numbers would need to be very large. For example, to detect one child who 
develops bronchiectasis in New Zealand (where prevalence is estimated at 33 per 100,000 
children aged 0-14 years)40 several thousand children would need to be enrolled. The ethical 
issues pertaining to performing CT chest and BAL are indeed significant. Thus, from a practical 
and ethical standpoint, it would be extremely difficult to justify a study with the ideal design. 
 
The major strengths of this study are the longitudinal nature of data collection and the inclusion 
of lower airway inflammatory and microbiological findings. However, as we only performed 
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bronchoscopy and BAL at a single time-point, the temporal relationship between infection with H. 
influenzae and development of bronchiectasis remains unclear. This does not, however, diminish 
the utility nor relevance of our findings. Irrespective of whether H. influenzae is a cause (or 
consequence) of bronchiectasis in young children, its presence in a child with recurrent PBB 
should alert the pulmonologist to the increased possibility of bronchiectasis, suggesting the need 
for closer monitoring and/or further investigation. This is a novel finding with direct clinical 
relevance to those managing children with chronic cough. 
 
Findings from this longitudinal cohort study provide further evidence to support a link between 
PBB and bronchiectasis in young children. We have shown that approximately 1 in 12 children 
with PBB are diagnosed with bronchiectasis at 2-year follow-up with many experiencing 
recurrent episodes of PBB. We have identified potential risk factors for bronchiectasis i.e. H. 
influenzae lower airway infection and recurrent episodes of PBB.  
 
Clinicians should be cognisant of the need to monitor children with PBB over time and to 
consider CT chest in those with risk factors for bronchiectasis. Further longitudinal studies, 
examining the outcomes of children with PBB, ideally using novel (low-radiation dose) imaging 
techniques are needed. Lastly, further research into the potential role of H. influenzae in the 
pathogenesis of bronchiectasis in children is needed to inform future preventative and therapeutic 
interventions.
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TABLES 
Table 1: Baseline demographic and clinical characteristics of study participants 
 PBB 
followed-up 
(N=106)  
         PBB total 
         (N=161) 
Controls 
(N=25)  
P-value1 
Sex, M:F 74:32  106:55  12:13    0.085 
 
Age - Mo 23 (14, 53)   22 (13, 50) 44 (7, 97)   0.061 
 
Prior pneumonia – X-ray 
confirmed2 
 
24 (23%)   35 (22%)   2 (8%)   0.109 
Household tobacco smoke 
exposure 
 
36 (34%)   55 (34%) 6 (24%)   0.662 
Aboriginal or Torres Strait 
Islander 
 
  3 (3%)   10 (6%) 0    0.363 
Current cough 89 (84%) 134 (83%) 2 (8%) <0.001 
Length of current cough – 
wks, median (IQR) 
 
26 (7, 52)   26 (6, 52) 0 <0.001 
 
Current antibiotics 16 (15%)   19 (12%) 1/15 (7%)   0.695 
 
>5 doctor visits past yr for 
cough 
95 (90%) 140 (87%) 3/15 (20%) <0.001 
Abbreviations: PBB followed-up = Subset of patients with PBB who completed 2-year follow-up; 
PBB total = all patients with PBB irrespective of whether 2-year follow-up was completed. 
1
 Comparison of ‘PBB total’ to controls; 2 Parent-reported  
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Table 2: Uni- and multi-variate analysis of risk factors for bronchiectasis (BE) in children 
with PBB 
Risk factor  Group 1 
BE present 
(N=13) 
Group 2 
BE absent 
(N=148) 
Odds ratio 
(95% CI)  
 
P-value 
Univariate analysis 
 
    
Sex, M:F  8:5  98:50 0.816 (0.25, 2.63) 0.733 
 
Recruitment age – 
mths, median (IQR) 
 
29 (10, 45)  22 (13, 50) 0.99 (0.97, 1.01) 0.521 
Prior pneumonia  
 
  3 (23%)  32 (22%) 1.09 (0.28, 4.19) 0.903 
 
Recurrent PBB  
(>3 ep/year)1 
 
11 (85%)  56 (38%) 9.04 (1.93, 42.27) 0.005 
Household tobacco 
smoke exposure 
 
  3 (23%)  52 (35%) 0.55 (0.14, 2.08) 0.377 
Maternal smoking in 
pregnancy 
 
  3 (23%) 18/85 (21%) 1.40 (0.34, 5.81) 0.647 
Aboriginal or Torres 
Strait Islander 
 
  1 (8%)    9 (6%) 1.29 (0.15, 11.03) 0.818 
No. children in 
household, median 
(IQR) 
 
≥2 siblings 
≥1 sibling 
  3 (2, 4) 
 
 
 
  8 (62%) 
13 (100%) 
   2 (2, 3) 
 
 
 
  47 (32%) 
123 (83%) 
1.28 (0.91, 1.80) 
 
 
 
3.44 (1.07, 11.08) 
- 
0.156 
 
 
 
0.039 
 
 
Childcare attendance, 
ever  
 
8/9 (89%) 71/82  (87%) 1.24 (0.14, 10.90) 0.847 
BAL organism     
Adenovirus positive 
(on PCR)2 
  
3/12 (25%) 26/138 (19%) 1.44 (0.36, 5.68) 0.606 
 
H. influenzae  11 (85%)   72 (49%) 5.81 (1.24, 27.10) 0.025 
M. catarrhalis    4 (31%)   43 (29%) 1.09 (0.32, 3.71) 0.896 
S. pneumoniae   3 (23%)  41 (28%) 0.78 (0.21, 2.99) 0.720 
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S. aureus    1 (8%)  12 (8%)  0.94 (0.11, 7.90) 0.958 
Multivariate analysis     
 
H. influenzae   7.60 (1.53, 37.79) 0.013 
 
≥2 siblings 
 
Recurrent PBB (>3 
ep/year) 
  3.53 (0.98, 12.70) 
 
11.48 (2.33, 56.50) 
0.054 
 
0.003 
 
1 As determined at 1-year time-point in study. 7 children had not reached the 1-year time-point, 
for the purposes of the multi-variate analysis these children were assumed to have non-recurrent 
PBB.   
2
 As compared to previously published rate of 4% (adenovirus positivity) in BAL samples of 
control children.8 
3 Beta-lactamase positive strains of H.influenzae were found in 17 of 83 (20.5%) of all isolates. 
Of these, 3 occurred in children from group 1 (27%) and 14 from group 2 (19%), Odds ratio=2.87, 
95%CI 0.70, 11.67; p for difference between groups 0.143. 
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Table 3: Survival analysis – PBB to bronchiectasis (Months) (n=161) 
 
HR (95% CI) P-value 
Univariable 
H. influenzae1 
 
5.81 (1.28 – 26.37) 
 
0.022 
≥2 siblings       3.18 (1.04 – 9.73) 0.042 
Recurrent PBB (>3 episodes/yr) 7.65 (1.67 – 34.92) 0.009 
  
 
Multivariable   
H. influenzae1 7.55 (1.66 – 34.28) 0.009 
Recurrent PBB (>3 episodes/yr) 9.77 (2.13 – 44.80) 0.003 
1
 Lower airway infection with H. influenzae defined as ≥104 cfu/ml growth on BAL fluid culture 
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FIGURE LEGENDS 
Figure 1: CONSORT diagram
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